Home Industries Reports Services About Us Publisher Contact us

Global 3D printed drugs Market Size Study, By Drug (Spritam and Others) and Regional (US and Rest of the World) Forecasts, 2017-2027

Covid-19 Impact on Market

Type: PDF

Status: Published

Categories: Pharma & Healthcare

Report Code : PHC202844

No. of Pages : 270

Global 3D printed drugs industry valued approximately USD XX Million in 2016 is anticipated to grow with a healthy growth rate of XX% over the forecast period 2017-2027. 3D printed drugs are created by 3D printing technology which are used to treat patients who suffering from dysphagia. This medicine is easy to swallow and helpful for patients suffering from dysphagia. Increase in demand for fast soluble drugs which can disperse easily in the mouth is the key factor that gives growth to the global 3D printed drugs market. Furthermore, rising incidence of epilepsy cases, continues technological developments in 3D printing technique, and growing awareness for 3D printing technology in the developing countries are the major drivers of the market. However, concerns such as blueprint hacking and mislabeling of blueprint are going to hamper the market growth. Moreover, dicey regulatory scenario is another major restraint.
In 2016, Spritam is first 3D printed drug receive approval from the FDA. It is launched by Aprecia Pharmaceuticals. This medicine is currently active only in the U.S. region.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

Drug:
 Spritam
 Others
Regions:
 North America
o U.S.
 Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2015 to 2018
Base year – 2019
Forecast period – 2020 to 2027
Some of the key manufacturers involved in the market Aprecia Pharmaceuticals, GlaxoSmithKline Plc., Hewlett Packard Caribe, BV, LLC, 3D Printer Drug Machine, and FabRx Ltd. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Target Audience of the 3D printed drugs Market Study:

 Key Consulting Companies & Advisors
 Large, medium-sized, and small enterprises
 Venture capitalists
 Value-Added Resellers (VARs)
 Third-party knowledge providers
 Investment bankers
 Investors

Request For Request Sample

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any), so we can get back to you with a solution
Chapter 1. Research Methodology
1.1. Research Process
1.1.1. Data Mining
1.1.2. Analysis
1.1.3. Market Estimation
1.1.4. Validation
1.1.5. Publishing
1.2. Research Assumption
Chapter 2. Global 3D printed drugs Market Definition & Scope
2.1. Objective of The Study
2.2. Market Definition
2.3. Scope of The Study
2.4. Years Considered for The Study
2.5. Currency Conversion Rates
2.6. Report Limitation
Chapter 3. Executive Summary
3.1. Key Trends
3.2. Global & Segmental Market Estimates & Forecasts, 2015-2027 (USD Billion/Million)
Chapter 4. Global 3D printed drugs Industry Dynamics
4.1. Growth Prospects
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.2. Industry Analysis
4.2.1. Porter’s 5 Force Model
4.2.2. PEST Analysis
4.2.3. Value Chain Analysis
4.3. Analyst Recommendation & Conclusion
Chapter 5. Global 3D printed drugs Market by Drugs
5.1. Market Snapshot
5.2. 3D printed drugs Market, Sub Segment Analysis
5.2.1. Spritam
5.2.1.1. Market estimates & forecasts, 2015-2027 (USD Billion/Million)
5.2.1.2. Regional breakdown estimates & forecasts, 2015-2027 (USD Billion/Million)
5.2.2. Others
5.2.2.1. Market estimates & forecasts, 2015-2027 (USD Billion/Million)
5.2.2.2. Regional breakdown estimates & forecasts, 2015-2027 (USD Billion/Million)
Chapter 6. Global 3D printed drugs Market, Regional Analysis
6.1. 3D printed drugs Market, Regional Market Snapshot (2015-2027)
6.2. North America 3D printed drugs Market Snapshot
6.2.1. U.S. 3D printed drugs Market Size Estimates & Forecasts, 2015-2027 (USD Billion/Million)
6.2.1.1. Market estimates & forecasts, 2015-2027 (USD Billion/Million)
6.2.1.2. Spritam breakdown estimates & forecasts, 2015-2027 (USD Billion/Million)
6.3. Rest of The World 3D printed drugs Market Snapshot
6.3.1. Market estimates & forecasts, 2015-2027 (USD Billion/Million)
6.3.2. Spritam breakdown estimates & forecasts, 2015-2027 (USD Billion/Million)
Chapter 7. Competitive Intelligence
7.1. Company Market Share (Subject to Data Availability)
7.2. Top Market Strategies
7.3. Company Profiles
7.3.1. Aprecia Pharmaceuticals
7.3.1.1. Overview
7.3.1.2. Financial (Subject to Data Availability)
7.3.1.3. Product Summary
7.3.1.4. Recent Developments
7.3.2. GlaxoSmithKline Plc.
7.3.3. Hewlett Packard Caribe
7.3.4. BV
7.3.5. FabRx Ltd
7.3.6. 3D Printer Drug Machine

Request For Research Methodology

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any), so we can get back to you with a solution
Zenith Market Insights

Report Code

PHC202844

Single User

US$ 3500

Multi User

US$ 5250

Corporate User

US$ 7000

Global 3D printed drugs Market Size Study, By Drug...

RD Code : PHC202844